Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 1, 1991 - Issue 5
Journal homepage
9
Views
1
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Overview: Present Developments in Cardiotonic Agents

V. Hagen Institute of Drug Research, Alfred-Kowalke-Str. 4, Berlin 0-1136, Germany
Pages 735-746 | Published online: 02 Mar 2011

References to Primary Literature

  • Creager, MA Massi, BM Faxon, DP Friedman, SD Kramer, BL Weiner, DA Ryan, TJ Topic, N Mellidosian, CD Acute and long-term effects of enalapril on the cardiovascular response to exercise and tolerance in patients with congestive heart failure J. Am. Coll. Cardiol. 1985 1 163.
  • The Consensus Trail Study Group Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N. Engl J. Med. 1987 316 1429.
  • Tjon-A-Meew, L Hess, OM Greminger, P Maire, R Jenni, R Krayenbuehl, HP A comparison between enalapril and captopril in the treatment of chronic heart failure. Z. Kardiol. 1990 79 429.
  • Alousi, AA Farah, AE Lesher, GY Opalka, CJ Cardiotonic activity of amrinone Win 40680 [5-amino-3,4′bipyridin-6(1H)-one]. Circ. Res. 1979 45 666.
  • Alousi, AA Johnson, DC Pharmacology of the bipyridines: Amrinone and milrinone. Circulation 1986 73 Suppl III 10.
  • Braunwald, E Sonnenblick, EH Chakrin, LW Schwarz, RP Milrinone: Investigation of new inotropic therapy for congestive heart failure. Schwarz, RP Raven Press New York 1984.
  • Dage, RC Roebel, LE Hsieh, CP Weinert, DL Woodward, JK Cardiovascular properties of a new cardiotonic agent: MDL 17043. J. Cardiovasc. Pharmacol. 1982 4 500.
  • Uretsky, BE Generalovich, T Reddy, PS Spangenberg, RB Folansbee, WB The acute hemodynamic effects of a new agent, MDL 17043, in the treatment of congestive heart failure. Circulation 1983 62 823.
  • Evans, DB Weishaar, RE Kaplan, HR Strategy for the discovery and development of a positive inotropic agent. Pharmacol. Therap. 1982 16 303.
  • Colucci, WS Wright, RF Braunwald, E New positive inotropic agents in the treatment of congestive heart failure. N. Engl J. Med. 1986 314 290 and 314: 349.
  • Weber, KT Gill, SK Janicki, JS Maskin, CS Jain, MC Newer positive inotropic agents in the treatment of congestive heart failure. Current status and future directions. Drugs 1987 33 503.
  • Wetzel, B Hauel, N New cardiotonic agents - a promising approach for treatment of heart failure. TIPS 1988 9 166.
  • Buschauer, A Development of new positive inotropic drugs: Search for a digitalis replacement. Pharm. Ztg. Wiss. 1989 134 3.
  • Weishaar, RE Kaplan, HR Positive inotropic and vasodilator agents for the treatment of heart failure and hypertension: A survey of mechanisms and agents. Current Cardiovas. Patents 1990 2 683.
  • Scholtysik, G Salzmann, R Berthold, R Herzig, JW Quast, U Markstein, R DPI 201–106, a novel cardiotonic agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging, and coronary dilatory properties. Naunyn-Schmiedeberg's Arch. Pharmacol. 1985 329 316.
  • Gerard, JL Berdeaux, A Giudicell, JF Cardiac and hemodynamic effects of S(-)- and R(+)- DPI 201–106 and of racemic DPI 201–106 in conscious dogs. Eur. J. Pharmacol. 1990 184 323.
  • Siegl, PKS Garcia, ML King, UV Kaczorowski, GJ Interaction of the inotropic stimulant DPI 201–106 with cardiac calcium channels. Fed. Proc. 1987 46 372.
  • Herzog, JW Quast, U Increase in Ca++ sensitivity of myocardial contractile structures by DPI 201–106: J. Mol. Cell Cardiol. 1984 16 Suppl 3 abstract 6.
  • Scholtysik, G Cardiac Na+ channel activation as a positive inotropic principle. J. Cardiovasc. Pharmacol. 1989 14 Suppl 3 S24.
  • Scholtysik, G Sodium current modulation and regulation of myocardial inotropy. Symposium: New trends in pharmacology and pathophysiology of heart muscle contraction. Alterations in myocardial failure. Hamburg 1990.
  • Wang, G Dugas, M Armah, BI Honerjăger, P Sodium channel comodification with full activator reveals veratrine reaction dynamics. Mol. Pharmacol. 1990 37 144.
  • Brasch, H Iven, H Influence of BDF 9148 on contractile force and action potentials of isolated guinea-pig atria and papillary muscles. Eur. J. Pharmacol. 1990 183 2226.
  • Lathrop, DA Schwartz, A Evidence for possible increase of sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC-8212. Eur. J. Pharmacol. 1985 117 391.
  • Haleen, SJ Steffen, RP Sircar, I Major, TC Taylor, MD Pugsley, TA Weishaar, RE PD 122–860: A novel dihydropyridine with sodium channel stimulating and calcium channel blocking properties. J. Pharmacol. Exp. Therap. 1989 250 22.
  • Yatani, A Imoto, Y Schwartz, A Brown, AM New positive inotropic agent OPC-8212 modulates single CA2+ channels in ventricular myocytes of guinea pig. J. Cardiovasc. Pharmacol 1989 13 812.
  • Lathrop, DA Varro, A Schwartz, A Rate-dependent electrophysiological effects of OPC-8212: Comparison to sotalol. Eur. J. Pharmacol. 1989 164 487.
  • Taira, N Endoh, M Iijima, T Satoh, K Yanagisawa, T Yamashita, S Maruyama, M Kawada, M Morita, T Wada, Y Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart. Arzneim. Forsch. 1984 34 347.
  • Durant, GY Duncan, WAM Ganellin, CR Parsons, ME Blakemore, RC Rasmussen, AC Impromidine (SK & F 92676) is a very potent and specific agonist for histamine H2-receptors. Nature 1978 276 403.
  • Baumann, G Permanetter, B Wirtzfeld, A Possible value of H2 receptor agonists for treatment of catecholamine-insensitive congestive heart failure. Pharmacol. Ther. 1984 24 165.
  • Buschauer, A Synthesis and in vitro pharmacology of arpromidine and related phenyl (pyridylalkyl) guanidines, a potential new class of positive inotropic drugs. J. Med. Chem. 1989 32 1963.
  • Lampe, JW Hanna, RG Piscitelli, TA Chou, YL Erhardt, PW Lumma, WC Greenberg, CS Ingebretsen, WR Marshall, DC Wiggins, J Cardiotonic Agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists. J. Med. Chem. 1990 33 1688.
  • Herzig, JW Feile, K Ruegg, JC Activating effects of AR-L 115 BS on the Ca++ sensitive force, stiffness, and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle. Arzneim. Forsch. 1981 31 188.
  • Solaro, RJ Ruegg, JC Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115 BS, a novel cardiotonic agent. Circ. Res. 1982 51 290.
  • Van Meel, JCA Zimmermann, R Diederen, W Erdman, E Mrwa, U Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole. Biochem. Pharmacol. 1988 37 213.
  • Weishaar, RE Cain, MH Bristol, JA A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 1985 28 537.
  • Parsons, WY Ramkumar, V Stiles, GL Mol. Pharmacol. 1988 33 441.
  • Ruegg, JC Pfitzner, G Eubler, D Zeugner, C Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzim- idazol-5-yl]5-methyl-3(2H)-pyridazinone. Arzneim. Forsch. 1984 34 1736.
  • Van Meel, JCA Effects of some cardiotonic agents on contractility of skinned fibres from mammalian heart. Arzneim. Forsch. 1987 37 679.
  • Lues, I Siegel, R Harting, J Effect of isomazole on the responsiveness to calcium of the contractile elements in skinned cardiac muscle fibre of various species. Eur. J. Pharmacol 1988 146 145.
  • Freund, P Mŭller-Beckmann, B Strein, K Fling, L Rueggy, JC Ca++-sensitising effect of BM 14.478 on skinned cardiac fibres of guinea pig papillary muscle. Eur. J. Pharmacol. 1987 136 243.
  • Kitada, Y Narimatsu, A Matsumura, N Endo, M Contractile proteins: Possible targets for the cardiotonic action of MCI-154 a novel cardiotonic agent. Eur. J. Pharmacol. 1987 134 229.
  • Herzig, JW Botelho, LH Solaro, RJ Myofibrillar Ca++ activation and heart failure -Ca++ sensitization by the cardiotonic agent APP 201–533. Basic Res. Cardiol. 1989 84 Suppl. 1 117.
  • Miller, DJ Steele, DS The calcium sensitising effect of ORG 30029 in saponin - or triton-skinned rat cardiac muscle. Br. J. Pharmacol. 1990 100 843.
  • Lee, JA Allen, DG Calcium sensitizers. A new approach to increasing the strength of the heart. Br. Med. J. 1990 300 551.
  • Fritsche, R Scheld, HH Mulch, J Trach, V Gerstenberg, W Van Meel, JCA Hehrlein, W Effect of pimobendan on calcium sensitivity of skinned fibre isolated from human papillary muscles. Br. J. Pharmacol. 1986 89 751P.
  • Smith, SJ England, P The effects of reported sensitizers on the rates of Ca++ release from cardiac troponin C and the troponin-tropomyosin complex. Br. J. Pharmacol. 1990 100 779.
  • Bristol, JA Sircar, I Moos, WH Evans, DB Weishaar, RE Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: Novel positive inotropic agents for the treatment of congestive heart failure. J. Med. Chem. 1984 27 1099.
  • Erhardt, PW Hagedorn, AA Davey, D Pease, CA Venepalli, BR Griffin, CW Gomez, RP Wiggins, JR Ingebretse, WR Pang, D Cantor, E Cardiotonic agents. 5. Fragments from the heterocycle-phenyl-imidazole pharmacophore. J. Med. Chem. 1989 32 1173.
  • Davis, A Warrington, BH Vinter, JG Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors. J. Computer-Aided Molecular Design 1987 1 97.
  • Schnettler, RA Dage, RC Palopoli, FP 4-Aryl-1,3-dihydro-2H-imidazol-2-ones: A new class of cardiotonic agents. 2. Effect of 4-Pyridoyl substituents and related compounds. J. Med. Chem. 1986 29 860.
  • Alvarez, R Banerjee, GL Bruno, JJ Jones, GL Littschwager, K Strosberg, AM Venuti, MC A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol. Pharmacol. 1986 29 554.
  • Bandurco, VT Schwender, CF Bell, SC Combs, DW Kanojia, RM Levine, SD Mulvey, DM Appollina, MA Reed, MS Malloy, EA Falotico, R Moore, JB Tobia, AJ Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2-(1H)quinazolinones. J. Med. Chem. 1987 30 1421.
  • Hayes, JS Pollock, GD Wilson, H Bowling, N Robertson, DW Pharmacology of LY 195 115. a potent, orally active cardiotonic with long duration of action. J. Med. Chem. 1987 9 425.
  • Reeves, ML Gristwood, RW Leigh, BK England, PJ SK&F 94836 a potent inotropic agent is a selective inhibitor of type III phosphodiesterase activity from several tissues. Br. J. Pharmacol. Proc. Suppl. 1987 92 773P.
  • Bagli, J Bogri, T Palameta, B Rakhit, S Peseckis, S MC Quillan, J Lee, DKH Chemistry and positive inotropic effect of pelrinone and related derivatives. A novel class of 2-methylpyrimidones as inotropic agents. J. Med. Chem. 1988 31 814.
  • Salzmann, R Scholtysik, G Markstein, R Bormann, G Pharmacological actions of DPN 205–734, a novel cardiotonic agent. J. Cardiovasc. Pharmacol. 1988 12 451.
  • Maruyama, M Kamiya, J Kaiho, T Kobari, T Cardiovascular properties of MS-857, a new and potent cardiotonic agent, on normal and failing hearts. J. Cardiovasc. Pharmacol. 1988 12 579.
  • Miyake, S Shiga, H Koike, H Mizuno, H Yorikane, R Oda, T Ijima, Y Kumakura, S Morisawa, Y Cardiovascular pharmacology of RS-1893, an orally active cardiotonic agent with arterial and venous vasodilator actions. Japan J. Pharmacol. 1988 47 273.
  • Alabaster, CT Bell, AS Campbell, SF Ellis, P Henderson, CG Morris, DS Roberts, DA Ruddock, KS Samuels, GMP Stefaniak, MH 2(1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. J. Med. Chem. 1989 32 575.
  • Bôhm, M Schwinger, RHG Erdmann, E Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for therapy with positive inotropic agents. Klin. Wochenschr. 1990 68 887.
  • Ogawa, T Ohara, H Tsunoda, H Kuroki, J Shoji, T Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. Arzneim. Forsch. 1989 39 33.
  • Combs, DW Rampulla, MS Bell, SC Klaubert, DH Tobia, AJ Falotico, R Haertlein, B Lakas-Weiss, C Moor, JB 6-Benzoxazinylpyridazi-3-ones. Potent long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem. 1990 33 380.
  • Barrett, JA Waltmann, RF Swillo, RS Kasiewski, C Faith, WC Campbell, HF Perrone, MH Pharmacology of RGW-2938: A cardiotonic agent with vasodilator activity. J. Cardiovasc. Pharmacol. 1990 16 537.
  • Shahid, M Martorana, MG Cottney, JE Marshall, RJ Pharmacological and biochemical effects of the cardiotonic agent ORG 10325 in isolated cardiac and vascular tissue preparations. Br. J. Pharmacol. 1990 100 735.
  • Mertens, A Friebe, W-G Mŭller-Beckmann, B Kampe, W Kling, L Von Der Saal, W Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities. J. Med. Chem. 1990 33 2870.
  • Matthews, DP McCarthy, JP Whitten, JP Kastner, PD Barney, CL Marshall, FN Ertel, MA Burkhard, T Shea, PJ Kariya, T Synthesis and cardiotonic activity of novel biimidazoles. J. Med. Chem. 1990 33 317.
  • Coates, WC Prain, HD Reeves, ML Warrington, BH 1,4-Bis-(3-oxo-2,3-dihydropyridazin-6-yl)-benzene analogues: Potent phosphodiesterase inhibitors and inodilators. J. Med. Chem. 1990 33 1735.
  • Armah, BI Stenzel, W Saterinone (BDF 8634): A different concept for pharmacotherapy of congestive heart failure. Drugs Future 1989 14 445.
  • Von Der Leyen, H Schmitz, W Scholz, H Scholz, J New positive inotropic agents acting by phosphodiesterase inhibition or alpha1-adrenergic stimulation. Pharmacol Research. 1989 21 329.

References to Patent literature

  • Heumann Pharma GmbH & Co EP 0339208.
  • Dage, R EP 0268146 A A, CV2197 1987 Current Cardiovasc. Patents (1990) 2(6):522.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.